Contract Research Organization (CRO) / Preclinical Drug Discovery Services
Strategic Profile
Growth in global R&D spending and greater outsourcing by biopharma are fueling rising demand for Inotiv's expanded preclinical CRO services, with operational efficiencies, strategic acquisitions, and focus on animal welfare and accreditation driving margin stability and long-term earnings growth. Recent strategic initiatives include integrating LifeNet Health's TruVivo® platform into its Discovery and Translational Sciences business, using primary human hepatocytes to build physiologically relevant in vitro models that align preclinical models with human biology.
Cyborg Score Rationale
FY2025 revenue grew 4.5% to $513.0M with operating losses narrowing to $30.9M (down 64.2% YoY), demonstrating improving profitability trajectories. However, high fixed costs, integration risks, and evolving alternatives to animal testing alongside rising debt costs create uncertainty in revenue predictability and may undermine traditional revenue streams.
Top Insights
FY2025 revenue growth of 4.5% to $513M with strong 23.5% Q3 growth, though operating losses improved significantly by 64.2% YoY
Recently integrated TruVivo® human hepatocyte platform to enhance translational predictivity and expand human-relevant tissue models
DSA segment showing strength with 15.7% Q4 growth and $138.2M backlog; company ranked 182nd on Deloitte Tech Fast 500 with 448% revenue growth FY2021-2024
Facing liquidity and refinancing pressures; company engaged Perella Weinberg Partners for debt refinancing and sold U.S. properties to repay term loan principal
Named Competitors
Integrated Contract Research Services — Large-scale preclinical and clinical CRO services
Life Sciences Tools & Services — Diversified life sciences platform and instrumentation
Integrated Drug Development — Global preclinical and clinical development services
Recent Developments
(February 2026) Q1 FY2026 results announced with continued operational improvements
(January 2026) Strategic integration of LifeNet Health's TruVivo® platform into Discovery and Translational Sciences business
(November 2025) Ranked 182nd on Deloitte Technology Fast 500 with 448% revenue growth over measurement period
(August 2025) Cybersecurity incident disclosed with data access under evaluation; engaged advisors for debt refinancing
Open the full interactive Inotiv, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.